Phaseline

Companies › Beijing Sungen Biomedical Technology

Beijing Sungen Biomedical Technology: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology, Cardiovascular, Gastroenterology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SGC001 injection–Phase 2Acute Anterior ST-Segment Elevation Myocardial Infarction; Acute PancreatitisApr 2027
SGT003–Phase 1Advanced Solid TumorDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07306182SGC001 injectionPhase 2Acute Anterior ST-Segment Elevation Myocardial InfarctionCardiovascularApr 2027
NCT07803965SGC001 injectionPhase 2Acute PancreatitisGastroenterologyNov 2027
NCT07811037SGT003Phase 1Advanced Solid TumorOncologyDec 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Zhejiang Doer Biologics Salubris Biotherapeutics Institut de Recherches Internationales Servier (I.R.I.S.) Hinova Pharmaceuticals HighField Biopharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.